Safety of Rapid-Acting Insulin Analogs Versus Regular Human Insulin

被引：10

作者：

Kitabchi, Abbas E. ^{[1
]}

Gosmanov, Aidar R. ^{[1
]}

机构：

[1] Univ Tennessee, Hlth Sci Ctr, Div Endocrinol Diabet & Metab, Memphis, TN 38163 USA

来源：

AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2012年 / 344卷 / 02期

关键词：

Diabetes; Hypoglycemia; Insulin; Pharmacokinetics; Pharmacodynamics; IMPAIRED GLUCOSE-TOLERANCE; TYPE-1 DIABETIC PREGNANCY; GLYCEMIC CONTROL; SOLUBLE INSULIN; RISK-FACTOR; ASPART; HYPOGLYCEMIA; MANAGEMENT; GLULISINE; EFFICACY;

D O I：

10.1097/MAJ.0b013e3182449ff9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Insulin is the most effective treatment for both type 1 and type 2 diabetes mellitus. There are several differences in the safety profiles of each type of insulin, including rapid-acting insulin analogs and regular human insulin. The pharmacokinetic and pharmacodynamic properties of those insulin types also differ, as do their safety parameters. Treatment with rapid-acting analogs results in less hypoglycemia overall and decreased frequency of both severe and nocturnal hypoglycemia. In addition, the more rapid onset and shorter duration of action of rapid-acting insulin analogs are associated with greater control of postprandial glucose than regular human insulin. This review will describe the similarities and differences between the safety profiles of rapid-acting insulin analogs.

引用

页码：136 / 141

页数：6

共 50 条

[41] Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine - a novel, rapid-acting, human insulin analogue.
Becker, RHA
Frick, AD
Wessels, DH
Scholtz, HE
DIABETOLOGIA, 2003, 46 : A268 - A268
[42] Pharmacokinetics of a rapid-acting human insulin analogue, insulin aspart, in children and adolescents with type 1 diabetes
Mortensen, H
Olsen, B
Li'ndholm, A
DIABETES, 1999, 48 : A358 - A358
[43] Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, is independent of hepatic function
Lyness, W
Tyler, J
Lawrence, A
DIABETES, 2001, 50 : A442 - A442
[44] Efficacy of Rapid-Acting and Long-Acting Insulin Analogs in Japanese Patients with Type 1 Diabetes Mellitus
Ozaki, Nobuaki
Nomura, Yoshio
Wanibe, Harumatsu
Yamamori, Ikuo
Oiso, Yutaka
DIABETES, 2009, 58 : A524 - A524
[45] Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs
Lindström, T
Hedman, CA
Arnqvist, HJ
DIABETES CARE, 2002, 25 (06) : 1049 - 1054
[46] Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
Siebenhofer, A.
Plank, J.
Berghold, A.
Jeitler, K.
Horvath, K.
Narath, M.
Gfrerer, R.
Pieber, T. R.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02):
[47] Long-acting insulin analogs versus human insulins
Garg, Satish K.
Naik, Ramachandra G.
DIABETES TECHNOLOGY & THERAPEUTICS, 2008, 10 (05) : 331 - 332
[48] Macro- and Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Rapid-Acting Insulin Analogues or Human Regular Insulin: a Retrospective Database Analysis
Rathmann, W.
Schloot, N. C.
Kostev, K.
Reaney, M.
Zagar, A. J.
Haupt, A.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (02) : 92 - 99
[49] CYTOTOXIC EFFECT OF THREE COMMERCIAL RAPID-ACTING INSULIN ANALOGS AND THEIR PHENOLIC EXCIPIENTS ON FOUR HUMAN IMMUNE CELL TYPES
Woodley, W. D.
Gerth, S. S.
Morel, D. R.
Borchert, K.
Godfrey, L.
Alarcoen, J.
Chandler, L.
Herrmann, N.
Pettis, R. J.
Bolick, N. G.
DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A115 - A116
[50] Efficacy and Safety Comparison between U-100 Human Regular Insulin and Rapid-Acting Insulin When Delivered by V-Go Wearable Insulin Delivery in an Older Type 2 Diabetes Population
Sutton, David R.
Mora, Pablo F.
Gore, Ashwini
Baliga, Bantwal
Goldfaden, Rebecca F.
Nikkel, Carla C.
Sink, John H., II
Adams-Huet, Beverley A.
DIABETES, 2020, 69

← 1 2 3 4 5 →